Global Molecular Diagnostics Market – Industry Trends and Forecast to 2030

분자 진단 시장 분석 및 규모

전 세계적으로 감염성 질환과 암의 발병률이 증가함에 따라 분자 진단법의 채택이 증가했습니다. 주요 시장 참여자들은 현재 주로 분자 진단법의 기술적 발전에 집중하고 있습니다. 또한 COVID-19 기간 동안 진단 산업이 코로나바이러스를 검출하기 위한 새롭고 신속한 진단 키트를 개발하기 위한 경쟁으로 많은 성장에 직면한 것으로 나타났습니다. Thermo Fisher Scientific은 2021년에 진단 사업부가 150% 성장하여 매출이 59% 증가했다고 보고했습니다.

Data Bridge Market Research는 2022년에 201억 달러였던 분자 진단 시장이 2030년까지 547억 6천만 달러로 증가할 것으로 분석하고, 2023년부터 2030년까지 예측 기간 동안 13.3%의 CAGR을 보일 것으로 예상합니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

분자 진단 시장 범위 및 세분화

시장 정의

분자진단은 조직이나 체액에서 DNA, RNA, 단백질과 같은 분자를 검사하여 유전성 질환, 감염성 질환 , 신경계 질환, 심혈관 질환 등의 질병을 검출할 수 있습니다. 질량 분석법, PCR, 차세대 시퀀싱, 현장 하이브리다이제이션, 분자 영상 등과 같은 수많은 방법이 여러 질병을 진단하는 데 사용됩니다. 분자진단은 DNA 서열 분석, 유전자 발현 프로파일링, 바이오마커 식별과 같은 강력한 기술을 사용하여 장애를 올바르게 식별합니다.

글로벌 분자진단 시장 역학

운전자

• 노인 인구 증가

전 세계적으로 노령 인구가 증가함에 따라 심혈관 질환, 암, 비만, 신경계 질환, 당뇨병 등 여러 질병에 걸릴 위험이 급증하고 있습니다. 유엔 보고서에 따르면 2020년 전 세계적으로 65세 이상의 인구는 약 7억 2,700만 명이었습니다. 이에 더해 2050년까지 80세 이상의 인구가 두 배로 늘어날 것으로 예상됩니다. 노령 인구는 복합 질환, 면역 기능 저하, 노화와 관련된 생리적 변화로 인해 여러 질병을 앓을 가능성이 더 높습니다. 따라서 이 요인은 시장 성장을 촉진합니다.

• PCR의 높은 사용

PCR is highly used in CROs, research institutes, and hospitals, enhancing the market growth rate. The growing use of high-throughput PCR technology to detect infectious and genetic diseases is anticipated to surge market growth. For instance, Seegene announced the launch of its upcoming Allplex SARS-CoV-2 Fast PCR Assay in 2022. The test has a turnaround time of 60 minutes and thus is appropriate for mass testing. Thus, this factor boosts market growth.

Opportunities

• Increasing Demand for Molecular Diagnostics in Point-of-Care Setting

In recent years, molecular diagnostic platforms have been widely used in PoC settings. Numerous companies are designing molecular diagnostic platforms and assays for POC or near-patient testing. In addition to this, the increasing development of new assays that provide quick PoC results is estimated to enhance market growth. For instance, Abbott launched a molecular point of care test, the ID NOW COVID-19 test, to diagnose COVID-19 in less than 5 minutes in 2020. Thus, this factor boosts market growth.  

• Increasing Prevalence of HIV

The increasing incidence of infectious diseases is anticipated to boost market growth over the forecast period. The growing occurrence of STIs, such as HIV and HPV, is anticipated to enhance the market growth as all these diseases demand a high rate of molecular tests. As per the WHO records, the prevalence of HIV was approximately 37.7 million and 1.5 million, respectively, in 2020. Additionally, people who have HIV are highly vulnerable to other infections, such as tuberculosis. All these infectious diseases demand multiple molecular tests, which will further help in faster treatment processes. Thus, this factor boosts market growth.

Restraints/Challenges

• Increasing Regulatory Approvals

The regulatory framework for approval is the main limiting factor in the market's growth. Many times, inaccurate results may be attained because of some fault in the diagnostic kits or an untrained person performing the test. Thus, strict regulation has been related to the approval process. Thus, this factor is restricting the market growth.

This molecular diagnostics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the molecular diagnostics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In 2020, Roche Diagnostics India launched the Cobas 8800 and the Cobas 6800 at the National Institute of Cholera and Enteric Diseases, Kolkata,  to help the SARS CoV-2 diagnostic testing. The Roche Cobas 6800/8800 systems deliver test findings in a time of three and a half hours and allow greater operational efficiency, flexibility, and the quickest time-to-results.
• In 2021, Roche completed the acquisition of TIB Molbiol Group. TIB Molbiol Group has about 45 CE-IVD-approved assays for diagnosing inherited genetic testing, infectious diseases, transplant medicine, and hematology testing.

Global Molecular Diagnostics Market Scope

The molecular diagnostics market is segmented on the basis of products, technology, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Products

• Reagents and Kits
• Instruments
• Services and Software

 Technology

• Mass Spectrometry (MS)
• Capillary Electrophoresis
• Next Generation Sequencing (NGS)
• Chips and Microarray
• Polymerase Chain Reaction (PCR)-Based Methods
• Cytogenetics
• In Situ Hybridization (ISH or FISH)
• Molecular Imaging
• Others

Application

• Oncology
• Breast Cancer
• Colorectal Cancer
• Lung Cancer
• Prostate Cancer
•  Other Cancers
• Pharmacogenomics
• Microbiology
• Prenatal Tests
• Tissue Typing
• Blood Screening
• Cardiovascular Diseases
• Neurological Diseases
• Infectious Diseases
• COVID-19
• Hepatitis
• HIV
• CT/NG
• HAI
• HPV
• Tuberculosis
• Influenza
• Others
• Others

End User

• Hospital
• Clinical Laboratories
• Academics

Molecular Diagnostics Market Regional Analysis/Insights

The molecular diagnostics market is analyzed and market size insights and trends are provided by products, technology, application and end user as referenced above.

The countries covered in the molecular diagnostics market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the molecular diagnostics market because of the increased per capita healthcare expenditure and increasing demand for better healthcare facilities. Also, a high standard of living and consumer awareness about early diagnosis, and the well-established healthcare system are major factors for the market growth. 

Asia-Pacific is expected to witness significant growth due to the high elderly population, growing incidence of cancer and varied infectious disease in countries such as China and India, and the advanced healthcare infrastructure within the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The molecular diagnostics market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for molecular diagnostics market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the molecular diagnostics market. The data is available for historic period 2011-2021.

Competitive Landscape and Molecular Diagnostics Market Share Analysis

The molecular diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to molecular diagnostics market.

Some of the major players operating in the molecular diagnostics market are:

• F. Hoffmann-La Roche Ltd(Switzerland)
• Hologic, Inc., (U.S.)
• bioMérieux (France)
• Abbott (U.S.)
• QIAGEN (Netherlands)
• Thermo Fisher Scientific (U.S.)
• Siemens (Germany)
• Danaher (U.S.)
• Myriad Genetics Inc. (U.S.)
• Illumina Inc. (U.S.)
• Agilent Technologies Inc. (U.S.)
• BD (U.S), DiaSorin S.p.A (Italy)
• Grifols S.A. (Spain)
• Quidel Corporation(U.S.)
• Genetic Signatures (Australia)
• MDxHealth, Inc. (U.S.)
•  Exact Sciences Corporation (U.S.)
• Biocartis (Belgium)
• TBG Diagnostics Limited (Australia)
• GenMark Diagnostics Inc. (U.S.)
• Luminex Corporation (U.S.)
• HTG Molecular Diagnostics Inc. (U.S.)
• Vela Diagnostics (Singapore)
• Amoy Diagnostics Co., Ltd. (China)
• Molbio Diagnostics Pvt. Ltd. (India)
•  geneOmbio (India)

SKU-22116